TAS-102 in combination with bevacizumab is currently in clinical development for the third-line treatment of refractory metastatic colorectal cancer (mCRC). Colorectal cancer, also known as bowel cancer, is cancer that affects the large bowel (colon cancer) or the back passage (rectal cancer). Common symptoms of colorectal cancer include a change in bowel habits or bleeding from the back passage, weight loss, and anaemia. Although the exact cause of colorectal cancer is unknown, risk factors include smoking, alcohol consumption, family history of the disease, being overweight or obese, and being inactive. There is an outstanding need for treatments that extend survival and maintain quality of life for patients with mCRC.
TAS-102 with bevacizumab for treating refractory metastatic colorectal cancer after 2 previous therapies
TAS-102 in combination with bevacizumab is currently in clinical development for the third-line treatment of refractory metastatic colorectal cancer (mCRC). Colorectal cancer, also known as bowel cancer, is cancer that affects the large bowel (colon cancer) or the back passage (rectal cancer). Common symptoms of colorectal cancer include a change in bowel habits or bleeding from the back passage, weight loss, and anaemia.
Interventions:
Bevacizumab (Avastin; R 435; RG 405; RG 435)
, Lonsurf; TAS-102 (fixed dose combination: Trifluridine; Tipiracil hydrochloride)
Indications:
Colorectal cancer
Year:
2023